HCA (HCA) COO Jon Foster granted 11,945 stock appreciation rights at $482.53
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
HCA Healthcare EVP and COO Jon M. Foster reported a grant of 11,945 stock appreciation rights (SARs) on HCA common stock at an exercise price of $482.53 per share. These SARs become exercisable in four equal annual installments beginning on January 29, 2027 and expire on January 29, 2036. The filing also lists indirect holdings of HCA common stock held through several trusts, including JMF Trust, LCF Trust, JMF Family Trust, and a 2025 GRAT.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Foster Jon M
Role
EVP and COO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Right | 11,945 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Appreciation Right — 11,945 shares (Direct);
Common Stock — 67,595 shares (Indirect, By JMF Trust (Spouse and Robert Nagel, Co-Trustees))
Footnotes (1)
- [object Object]
FAQ
What insider transaction did HCA (HCA) report for EVP and COO Jon M. Foster?
HCA reported that EVP and COO Jon M. Foster received 11,945 stock appreciation rights on HCA common stock. These derivative awards were granted on January 29, 2026, at an exercise price of $482.53 per share and are detailed as a new equity-based incentive.
How many stock appreciation rights were granted to HCA EVP and COO Jon M. Foster?
Jon M. Foster was granted 11,945 stock appreciation rights tied to HCA common stock. All 11,945 derivative securities are shown as beneficially owned following the reported transaction, with an exercise price of $482.53 and an expiration date of January 29, 2036.
What is the vesting schedule for Jon M. Foster’s HCA stock appreciation rights?
The stock appreciation rights vest in four equal annual installments beginning January 29, 2027. This means one-quarter of the 11,945 rights become exercisable each year over four years, subject to the terms and conditions of the award described in the filing.
What is the exercise price and expiration date of the HCA stock appreciation rights granted?
The stock appreciation rights have an exercise price of $482.53 per share and expire on January 29, 2036. They are derivative securities linked to HCA common stock and become exercisable over four years starting January 29, 2027, as disclosed.
Does this HCA Form 4 show any stock sales by Jon M. Foster?
The Form 4 reports an acquisition of 11,945 stock appreciation rights, coded as an “A” transaction. It does not list any dispositions of common stock; instead, it updates derivative holdings and restates indirect common stock positions held via several trusts.